Bruker Daltonics Appoints Mr. Seiichiro Tsurumaki as Assistant Vice President for Japan.To download high-resolution, print-ready JPEG JPEG in full Joint Photographic Experts Group Standard computer file format for storing graphic images in a compressed form for general use. JPEG images are compressed using a mathematical algorithm. images, click on the thumbnail image above. WARNING: these images are very large (800K+) Click here for caption Business Editors/Health/Medical Writers MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4608133 BILLERICA, Mass.--(BUSINESS WIRE)--April 5, 2004 Bruker Daltonics Inc., an operating company operating company A business that engages in transactions with outsiders. of Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ), announces that Mr. Seiichiro Tsurumaki has been appointed as its Assistant Vice President for Japan. Mr. Tsurumaki is responsible for the management of the Company's marketing, sales, applications, customer support and research activities in Japan, and he will also join the Bruker Daltonics global management team. Mr. Tsurumaki has over 20 years of experience in sales and marketing of molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller research instrumentation in Japan, particularly concerning life-science mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. systems. In 1994, he became MALDI-TOF-MS and LC-MS Sales Manager for Nihon Perseptive Ltd. In 2000, he was appointed Sales and Marketing Director of Bruker Daltonics K.K. and established a new applications and customer center in Tokyo, from which he expanded both our direct sales and support system and also organized a nation-wide network of distributors in Japan. In 2002, Mr. Tsurumaki moved Bruker Daltonics K.K. to larger facilities in Yokohama and established an expanded applications and technical support center to further enhance customer support. Frank Laukien, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bruker Daltonics, stated: "We are very pleased to have Seiichiro-san join our worldwide management team, while he continues to build our sales and customer support in Japan. In recent years, under his leadership, our business in Japan has grown very rapidly, and today we are recognized as a leading life-science mass spectrometry supplier by our customers in Japan. Significantly, Bruker Daltonics K.K. has recently also begun significant research and development activities in Japan, together with leading universities and government laboratories." Mr. Seiichiro Tsurumaki commented: "Our major focus in Japan has been proteomics, where the Bruker Daltonics mass spectrometry product line is particularly strong, using primarily MALDI-TOF MALDI-TOF Matrix Assisted Laser Desorption Ionization - Time of Flight (/TOF) and ion trap systems. I believe that our complete solutions, such as Proteineer(TM) for expression proteomics and ClinProt(TM) for biomarker discovery and clinical proteomics, have assisted many Japanese researchers in molecular biology and clinical diagnostics to enter the field of proteomics, without needing extensive background in mass spectrometry. We are now expanding into related life-science applications, such as glycomics and metabonomics, where in addition to the previously mentioned systems, ESI-TOF mass spectrometers, and of course the very exciting new hybrid Q-q-FTMS systems, are of high interest. A major new FTMS See Fusion FTMS. project for top-down proteomics is being planned." "In order to support our growing customer base, we are greatly expanding our Yokohama Technical Support Center, and we are also opening an Osaka applications laboratory to strengthen our support organization in Western Japan. We wish to have a flexible organization that is responsive to the changing applications, training and support requirements of life-science researchers from various fields in Japan." ABOUT BRUKER BIOSCIENCES Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements. MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4608133 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion